OVERLAND PARK, KS; January 10, 2023—(BUSINESS WIRE) Dr. Vince Clinical Research (DVCR), an early phase CRO specializing in Phase 1 trials, announced that it has administered the first dose of Aclaris Therapeutics’ ATI-2138, in a Phase 1 multiple ascending dose (MAD) study for an investigational oral compound being developed for the treatment of autoimmune diseases. The Phase 1 MAD study in healthy volunteers is being conducted at DVCR’s world-class clinical pharmacology unit.
The study will enroll 60 participants across 5 cohorts. Many features of the facility were engineered specifically with the conduct of ascending dose trials in mind, including dedicated vital signs machines at every bedside to enhance data quality for dose escalation meetings and luxurious amenities to improve participant retention throughout the entire duration of the trial.
George Atiee, MD, is serving as the Principal Investigator on the trial. “I am honored and excited to be a part of this trial in ATI-2138’s development. Fortunately, the research campus has been purpose-built to further empower our operations team to deliver on our commitments,” said Dr. Atiee.
Dr. Vince Clinical Research looks forward to the successful completion of this trial and delivering on its promise to provide Smarter, Faster Data® to its biopharmaceutical Sponsors.
About Dr. Vince Clinical Research
Dr. Vince Clinical Research (DVCR) is a full-service contract research organization (CRO) specializing in early phase trials in both healthy normal volunteers and patient populations across a wide range of trial designs and multiple therapeutic areas such as neuroscience, psychiatry, substance abuse, pain, cardiometabolic disorders, infectious diseases and others. CRO services include project management, data management, biostatistics, monitoring, PK/PD analysis, medical writing as well as site feasibility and management for multi-center trials. Additionally, DVCR operates one of the most innovative and technologically advanced clinical pharmacology units in the world with over 90 beds for overnight confinement, a cGMP compliant pharmacy as well as luxurious amenities to support diverse study participant recruitment and retention. By leveraging technology and one of the country’s most experienced leadership teams in early clinical development, DVCR provides Smarter Faster Data® to their biopharmaceutical clients.
Website: https://sponsors.drvince.com
LinkedIn: https://www.linkedin.com/company/dr-vince-clinical-research/
For more information, contact:
Zach Bader
Vice President, Business Development
(913) 333-3000
Dr. Vince Clinical Research
zbader@drvince.com